Application of validated RP-HPLC method for simultaneous determination of docetaxel and ketoconazole in solid lipid nanoparticles

Journal of Chromatographic Science

Volumn 49, Issue 2, 2011, Pages 136-141

  Venishetty, Vinay Kumar ^a   Parikh, Nirali ^a,b   Sistla, Ramakrishna ^a   Ahmed, Farhan J ^c   Diwan, Prakash Vamanrao ^a,b  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^b NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^c HAMDARD UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78751539224     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chrsci/49.2.136     Document Type: Article

References (27)

1. M. C. Bissery, D. Guenard, F. Fueritte-Voegelein and F. Lavelle. Experimental antitumor activity of taxotere (RP 56976 NSC 628503) a taxol Analogue. Cancer Res 51:4845 (1991)
2. L. Mangatal, M. T. Adeline, D. Guenard, F. Gueritte-Voegelin and P. Potier. Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of taxol and analogues. Tetrahedron 45:4177 (1989)
3. F. Gueritte-Voegelin, D. Guenard, F. Lavelle, M. T. Legoff, L. Mangatal, and P. Potier. Relationships between the structure of taxol analogs and their antimitotic activity. J. Med Chem 34:992-998 (1991)
4. I. Ringel and S. B. Horwitz, Studies with RP 56976 (Taxotere): A semisynthetic analogue of taxol. J. Natl. Cancer Inst 83:288 (1991)
5. R. C. Heel, R. N. Brogden, A. Carmine, P. A. Morley, T. M. Speight, and G. S. Avery, Ketoconazole:A review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 23:1 (1982).
6. T. K. Daneshmend and D. W. Warnock. Clinical pharmacokinetics of ketoconazole. Clin. Pharmacokinet. 14:13 (1988).
7. P. M. Arlen, W. D. Figg, J. Gulley, M. C. Cox, W. M. Linehan and W. Dahut. Intramural approach to advanced prostate cancer. Clin. Prostate Cancer 1:153 (2002).
8. C. J. Logothetis. Docetaxel in the integrated management of prostate cancer. Current applications and future promise, Oncology (Williston Park). 16:63 (2002).
9. ®) in vitro: Involvement of the CYP3A subfamily in humans. Cancer Res. 56:1296 (1996).
10. S. J. Clarke and L. P. Rivory. Clinical pharmacokinetics of docetaxel. Clin. Pharmacokinet. 36:99 (1999).
11. V. Fischer, A. Rodriguez-Gascon, F. Heitz, R. Tynes, and A. E. Vickers. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A: Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab. Dispos. 26:802 (1998).
12. H. A. Bardelmeijer, M. Ouwehand, T. Buckle, M. T. Huisman, J. H. Schellens, J. H. Beijnen, and O. van Tellingen. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res. 62:6158 (2002).
13. Docetaxel combined with ketoconazole in treatment of breast cancer, http://clinicaltrials.gov/ct2/show/NCT00212095
14. Q. Huang, G.-J. Wang, J.-G. Sun, X.-L. Hu, Y.-H. Lu, and Q. Zhang. Simultaneous determination of docetaxel and ketoconazole in rat plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. Rapid Commun. Mass Spectrom. 21:1009-1018 (2007).
15. C. Brass, J. N. Galgiani, T. F. Blaschke, R. Defelice, R. A. O'Reilly, and D. A. Stevens. Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob. Agents Chemother. 21:151 (1982).
16. C. M. Riley and M. O. James. Determination of ketoconazole in the plasma, liver, lung and adrenal of the rat by high-performance liquid chromatography. J. Chromatogr. 377:287 (1986).
17. D. W. Hoffman, K. L. Jones-King, C. L. Ravaris, and R. D. Edkins. Electrochemical detection for high-performance liquid chromatography of ketoconazole in plasma and saliva. Anal. Biochem. 172:495 (1988).
18. M. B. Garg and S. P. Ackland. Simple and sensitive high-performance liquid chromatography method for the determination of docetaxel in human plasma or urine. J. Chromatogr. B Biomed. Sci. Appl. 748:383 (2000).
19. W. J. Loos, J. Verweij, K. Nooter, and G. Stoter. Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography. J. Chromatogr. B Biomed. Sci. Appl. 693:437 (1997).
20. S. F. Swezey, K. M. Giacomini, A. Abang, C. Brass, D. A. Stevens and T. F. Blaschke. Measurement of ketoconazole, a new antifungal agent, by high-performance liquid chromatography. J. Chromatogr 227:510 (1982).
21. R. A. Parise, R. K. Ramanathan, W. C. Zamboni, and M. J. Egorin. Sensitive liquid chromatography-mass spectrometry assay for quantitation of docetaxel and paclitaxel in human plasma. J. Chromatogr B. Analyt. Technol. Biomed. Life Sci. 783:231 (2003).
22. Y. L. Chen, L. Felder, X. Jiang, and W. Naidong. Determination of ketoconazole in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 774:67 (2002).
23. W. Hou, J. W. Watters, and H. L. McLeod. Simple and rapid docetaxel assay in plasma by protein precipitation and high-performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 804:263 (2004).
24. B. M. Rao, A. Chakraborty, M. K. Srinivasu, M. Lalitha Devi, P. Rajender Kumar, K. B. Chandrasekhar, A. K. Srinivasan, A. S. Prasad, and J. Ramanatham. A stability-indicating HPLC assay method for docetaxel. J. Pharm. Biomed. Anal. 41:676 (2006).
25. M. V. Vertzoni, C. Reppas, and H. A. Archontaki. Optimization and validation of a high-performance liquid chromatographic method with UV detection for the determination of ketoconazole in canine plasma. J. Chromatogr. B 839:62 (2006).
26. N. P. Horacio and J. D. Anthony. Revised USP System Suitability Parameters. IPC-USP 7th Annual Scientific Meeting (Feb. 6-7, 2008).
27. Z. Xu, L. Chen, W. Gu, Y. Gao, L. Lin, Z. Zhang, Y. Xi, and Y. Li. The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 30:226-232 (2009).